These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
356 related articles for article (PubMed ID: 28655599)
1. Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma. Voorhees PM; Gasparetto C; Moore DT; Winans D; Orlowski RZ; Hurd DD Clin Lymphoma Myeloma Leuk; 2017 Jul; 17(7):424-432. PubMed ID: 28655599 [TBL] [Abstract][Full Text] [Related]
2. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. Orlowski RZ; Nagler A; Sonneveld P; Bladé J; Hajek R; Spencer A; San Miguel J; Robak T; Dmoszynska A; Horvath N; Spicka I; Sutherland HJ; Suvorov AN; Zhuang SH; Parekh T; Xiu L; Yuan Z; Rackoff W; Harousseau JL J Clin Oncol; 2007 Sep; 25(25):3892-901. PubMed ID: 17679727 [TBL] [Abstract][Full Text] [Related]
3. Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. Orlowski RZ; Nagler A; Sonneveld P; Bladé J; Hajek R; Spencer A; Robak T; Dmoszynska A; Horvath N; Spicka I; Sutherland HJ; Suvorov AN; Xiu L; Cakana A; Parekh T; San-Miguel JF Cancer; 2016 Jul; 122(13):2050-6. PubMed ID: 27191689 [TBL] [Abstract][Full Text] [Related]
4. Pegylated liposomal Doxorubicin: a review of its use in the treatment of relapsed or refractory multiple myeloma. Plosker GL Drugs; 2008; 68(17):2535-51. PubMed ID: 19016577 [TBL] [Abstract][Full Text] [Related]
5. Phase I study of pegylated liposomal doxorubicin in combination with bortezomib for Japanese patients with relapsed or refractory multiple myeloma. Kusumoto S; Sunami K; Inagaki M; Iida S Int J Hematol; 2015 Jun; 101(6):578-84. PubMed ID: 25749662 [TBL] [Abstract][Full Text] [Related]
6. Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients. Romano A; Chiarenza A; Conticello C; Cavalli M; Vetro C; Di Raimondo C; Cunsolo R; Palumbo GA; Di Raimondo F Eur J Haematol; 2014 Sep; 93(3):207-13. PubMed ID: 24673398 [TBL] [Abstract][Full Text] [Related]
7. VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma. Siegel DS; Dimopoulos M; Jagannath S; Goldschmidt H; Durrant S; Kaufman JL; Leleu X; Nagler A; Offner F; Graef T; Eid JE; Houp J; Gause C; Vuocolo S; Anderson KC Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):329-334.e1. PubMed ID: 27025160 [TBL] [Abstract][Full Text] [Related]
8. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Sonneveld P; Hajek R; Nagler A; Spencer A; Bladé J; Robak T; Zhuang SH; Harousseau JL; Orlowski RZ; Cancer; 2008 Apr; 112(7):1529-37. PubMed ID: 18300257 [TBL] [Abstract][Full Text] [Related]
9. A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma. Waterman GN; Yellin O; Swift RA; Mapes R; Eades B; Ackerman E; Berenson JR Ann Hematol; 2011 Feb; 90(2):193-200. PubMed ID: 20809423 [TBL] [Abstract][Full Text] [Related]
10. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Dimopoulos M; Siegel DS; Lonial S; Qi J; Hajek R; Facon T; Rosinol L; Williams C; Blacklock H; Goldschmidt H; Hungria V; Spencer A; Palumbo A; Graef T; Eid JE; Houp J; Sun L; Vuocolo S; Anderson KC Lancet Oncol; 2013 Oct; 14(11):1129-1140. PubMed ID: 24055414 [TBL] [Abstract][Full Text] [Related]
11. A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma. Berenson JR; Yellin O; Kazamel T; Hilger JD; Chen CS; Cartmell A; Woliver T; Flam M; Bravin E; Nassir Y; Vescio R; Swift RA Leukemia; 2012 Jul; 26(7):1675-80. PubMed ID: 22354206 [TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma. Cohen A; Spektor TM; Stampleman L; Bessudo A; Rosen PJ; Klein LM; Woliver T; Flam M; Eshaghian S; Nassir Y; Maluso T; Swift RA; Vescio R; Berenson JR Br J Haematol; 2018 Jan; 180(1):60-70. PubMed ID: 29164606 [TBL] [Abstract][Full Text] [Related]
13. Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma. Vogl DT; Raje N; Jagannath S; Richardson P; Hari P; Orlowski R; Supko JG; Tamang D; Yang M; Jones SS; Wheeler C; Markelewicz RJ; Lonial S Clin Cancer Res; 2017 Jul; 23(13):3307-3315. PubMed ID: 28053023 [No Abstract] [Full Text] [Related]
14. A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma. Schroeder MA; Fiala MA; Huselton E; Cardone MH; Jaeger S; Jean SR; Shea K; Ghobadi A; Wildes T; Stockerl-Goldstein KE; Vij R Clin Cancer Res; 2019 Jul; 25(13):3776-3783. PubMed ID: 30952640 [TBL] [Abstract][Full Text] [Related]
15. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Badros A; Burger AM; Philip S; Niesvizky R; Kolla SS; Goloubeva O; Harris C; Zwiebel J; Wright JJ; Espinoza-Delgado I; Baer MR; Holleran JL; Egorin MJ; Grant S Clin Cancer Res; 2009 Aug; 15(16):5250-7. PubMed ID: 19671864 [TBL] [Abstract][Full Text] [Related]
16. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045 [TBL] [Abstract][Full Text] [Related]
17. Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma. Weber DM; Graef T; Hussein M; Sobecks RM; Schiller GJ; Lupinacci L; Hardwick JS; Jagannath S Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):319-24. PubMed ID: 23040438 [TBL] [Abstract][Full Text] [Related]
18. A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma. Ogawa Y; Ogura M; Tobinai K; Ando K; Suzuki T; Watanabe T; Ohmachi K; Uchida T; Hanson ME; Tanaka Y; Koh Y; Shimamoto T; Hotta T Int J Hematol; 2016 Jan; 103(1):25-33. PubMed ID: 26619834 [TBL] [Abstract][Full Text] [Related]
19. Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment. Bladé J; Sonneveld P; San Miguel JF; Sutherland HJ; Hajek R; Nagler A; Spencer A; Robak T; Cibeira MT; Zhuang SH; Harousseau JL; Orlowski RZ; Clin Lymphoma Myeloma; 2008 Dec; 8(6):352-5. PubMed ID: 19064400 [TBL] [Abstract][Full Text] [Related]
20. A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors. Dees EC; O'Neil BH; Lindley CM; Collichio F; Carey LA; Collins J; Riordan WJ; Ivanova A; Esseltine D; Orlowski RZ Cancer Chemother Pharmacol; 2008 Dec; 63(1):99-107. PubMed ID: 18327587 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]